Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...

Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which ...

Based on the significant unmet medical need in the treatment of GAD along with the initial clinical data from the Phase 2b ...

Novo Nordisk is investing $1.2 billion in a rare disease drugs facility in Denmark, weight-loss drugs surge American ...

Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to ...

Find insight on Novo Holdings, Malaysian glove sector and more in the latest Market Talks covering health care.

Danish pharma giant Novo Nordisk will make a significant investment of approximately $1.2 billion to construct a new ...

The pharmaceutical company will establish a production facility in Odense to accommodate multiple product types within the ...

Novo Holdings has completed regulatory conditions for its $16.5 billion acquisition of Catalent, aiming to increase production of Wegovy, a weight-loss drug. The deal includes selling three Catalent ...

【诺和诺德收购Catalent交易已获准完成】 诺和诺德当地时间12月14日宣布，与诺和控股收购美国合同制药商Catalent的审查相关的所有监管成交条件均已满足，双方现在可以自由完成交易。诺和诺德预计收购将在未来几天内完成。

诺和诺德 当地时间12月14日宣布，与诺和控股收购美国合同制药商Catalent的审查相关的所有监管成交条件均已满足，双方现在可以自由完成交易。诺和诺德预计收购将在未来几天内完成。

FTC approves Novo Holdings' $16.5B Catalent acquisition. Deal includes selling 3 facilities to Novo Nordisk for $11B, despite ...